Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 11, 2019

View Archived Issues

Mosquito diet drugs could block spread of multiple diseases

Gene therapy found effective in a mouse model of Fabry disease

Antidepressant also fights sepsis

Chronic inflammation leads to 'immunological scarring'

Orally active GPR119 agonist demonstrates hypoglycemic effects in rats

Discovery and preclinical characterization of novel pan-PIM kinase inhibitor

Ganglioside analogue modulates APP processing and function rescuing neurodegeneration in AD

Multifunctional carbazole-based dopamine agonists for the treatment of Parkinson's disease

Phase III data presented for pegunigalsidase alfa in the treatment of Fabry disease

uniQure presents updated data from phase IIb study of AMT-061 in hemophilia B

China's NMPA accepts IND filing for combination of CS-1001 and IMP-4297 for solid tumors

First patient treated in phase Ib/II study of ilixadencel with checkpoint inhibitors

Data from phase Ib/II trial of NVX-208 in acute ischemic stroke warrant further investigation

Phoenix Tissue Repair studies PTR-01 in patients with recessive dystrophic epidermolysis bullosa

New SUMO-1 activators discovered at the Icahn School of Medicine

Washington University and Saint Louis University patent antitubercular compounds

Jiangsu Aosaikang Pharmaceutical and collaborators patent EGFR inhibitors

Metallo-beta-lactamase inhibitors identified at Merck & Co.

New adenosine receptor antagonists disclosed by Girafpharma

Fortis initiates phase I study of FOR-46 in metastatic CRPC

Follicum selects drug candidate for diabetes and protection of beta cells

Lilly begins phase I study of LY-3405105 in advanced solid tumors

Alpine initiates first-in-human trial of dual ICOS/CD28 antagonist ALPN-101

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...